These results provide a tailwind for the recently launched medical technology strategy of the German government. The association welcomes the alliance between politics and industry to make regulation more efficient and to strengthen Germany as a location for innovation and supply. Small and medium-sized manufacturers in particular see an urgent need for action. Many believe that high regulatory hurdles and rising costs for energy, personnel and certification make Germany less attractive. The current authorisation regime in particular is seen as a brake on growth.
The political focus is now not only on reducing bureaucracy. Procedures are also to become more transparent and easier to plan. The regulatory framework should also be made simpler and more reliable. From the industry's perspective, this is the only way that innovation can reach patients more quickly and Germany can regain its competitiveness in global medtech competition.
Press release of the "BVMed - Bundesverband Medizintechnologie e.V." from 03.12.2025